Takeda backs microbiome biotech

By Staff Reporter

- Last updated on GMT

(Image: Getty/Gordan1)
(Image: Getty/Gordan1)

Related tags: Takeda, Enterome, Microbiome

Enterome completes Series E financing round, with Takeda returning to provide funds to the biotech.

Takeda is currently going through a phase of building out its pipeline with smaller scale deals, such as through a partnership with Evox​ and a treatment acquisition earlier this year​.

It has followed this up by being a backer of Enterome’s recent €46.3m ($52.6m) Series E financing round.

The two companies are already partnered on sibofimloc, a potential treatment for Chron’s disease, and previously signed a drug discovery collaboration for microbiome targets for gastrointestinal disorders.

The funds provided by Takeda will be used to progress the potential small molecule drug, sibofimloc, through development.

Regarding the rest of the funding, Enterome will look to progress its cancer immunotherapy, EO2401, which will see the drug candidate enter Phase I/II clinical studies in glioblastoma and adrenal tumors.

The potential treatment was generated by Enterome’s ‘OncoMimics’ platform, which creates microbiome-derived peptide antigens that mimic antigens expressed by tumor cells.

In the case of EO2401, the drug candidate expressed three peptide antigens that are present in glioblastoma and adrenal malignancies.

Beyond this candidate, the biotech is planning for its second OncoMimic candidate, EO2463, to enter the clinic in 2021 for the treatment of B-cell malignancies.

CEO of the company, Pierre Belichard, explained how the technology works: “[The] platform capitalizes on the well-described, constant interaction between the microbiome and the immune system, resulting in a pool of memory T cells directed against specific commensal bacterial antigens that we have identified.”

He continued, “We have discovered that some of these antigens bear striking similarity to those present on multiple cancer types and can induce a targeted, anti-tumor response.”

Correction: The piece previously indicated that Enterome was developing live biotherapeutics, this has been corrected to reflect Enterome's work developing potential small molecule treatments that are based on learnings from the microbiome.

Related topics: Clinical Development, Phase I-II

Related news

Related products

show more

What should a clinical metadata repository do?

What should a clinical metadata repository do?

Formedix | 26-Jul-2021 | Technical / White Paper

Choosing a clinical metadata repository (MDR) software can be a tough task as the capabilities and features of your chosen MDR could make or break your...

Adapting supply chains to new ways of working

Adapting supply chains to new ways of working

World Courier | 15-Jul-2021 | Technical / White Paper

COVID-19 has changed the way we operate. We have adapted our supply chain solutions to meet our clients’ requirements while following World Courier standard...

Empowering Clinical Trial Sponsors with Analytics

Empowering Clinical Trial Sponsors with Analytics

PerkinElmer | 14-Jul-2021 | Technical / White Paper

Is your Clinical Data Review creating problems or solving them? Take Control of Your Data. PerkinElmer Informatics Clinical Solutions, powered by Tibco...

What are the building blocks of DCTs?

What are the building blocks of DCTs?

Medable | 26-Apr-2021 | Technical / White Paper

How to create a seamless experience across eConsent, eCOA and more.

Over the past year, tremendous progress was made toward digitizing and...

Related suppliers

Follow us

Products

View more

Webinars